



**A.MENARINI**  
PHARMACEUTICALS IRELAND LTD  
*Healthcare for Life*

## **Patient Organisation Support Disclosure**

### **Methodological Note**

#### **1. Introduction**

This methodological note is intended to help readers understand how support from A. Menarini Pharmaceuticals Ireland Ltd (A. Menarini) to Patient Organisation (PO) within Ireland have been collated and reported.

#### **2. Definition of Support**

A.Menarini may support POs, in line with the IPHA Code of Practice and internal Ethical Codes, in the following ways:

- Projects of joint interest, which may include direct and indirect support
- Once off funding for a specific project or meeting, usually financial support
- Contracted services where A.Menarini contract a PO to perform a service.

All support will be defined in a contract between both parties prior to the provision of support.

#### **3. Patient Organisation Support categories and methodologies**

The IPHA disclosure template prescribes the following categories of PO Support:

- Financial support
- Significant indirect support
- Non-financial support
- Contracted services

POs have relevant bona fides checked and are qualified under an in-house SOP before going to contract. The nature of the support given – direct or indirect - is detailed in terms of expectations of input from the PO and from A.Menarini. All contracts are signed before a project or donation can proceed.

#### **4. Data Privacy**

Patient Associations are contractually obliged to at all times comply with all data privacy law requirements including the Data Privacy Act of 1988 and 2003, the Data Protection Directive 95/46/EC and the General Data Protection Regulation (GDPR).

#### **5. Financial Aspects**

The following must be noted with regards to methodology and business decisions associated with the collection and disclosure of the support:

- Data gathering – Transfer data is collated using the company's in house finance and reporting systems
- Timing: A.Menarini PO disclosures correspond to the period to which the event occurred for which the PO payment is being made. Therefore, following the standard accrual accounting concept, i.e. a payment made in 2024 relating to an event in 2023 will not be included in the 2024 report. Similarly a payment in 2023 being a deposit for a 2024 event will be disclosed in the 2024 PO report.



**A.MENARINI**  
PHARMACEUTICALS IRELAND LTD  
*Healthcare for Life*

## Patient Organisation Support Disclosure

### Methodological Note

- Currency: All PO supports are disclosed in Euro. Any payments incurred in other currencies are converted at the prevailing spot rates, corresponding to the cost to the company.
- VAT: Where applicable, VAT is included.
- Multi-year contracts: Transfers correspond to the payment amount and date. i.e. a 3-year contract with equal annual payments will be disclosed in 3 separate years.

## 6. Publication of report

Publication of data will be made on a report hosted on [www.menarini.ie](http://www.menarini.ie), updated by 30 June every year. The data will remain published for 3 years from the time of disclosure. A.Menarini are obliged to hold records for at least 5 years.

IR-MEN-24-2025

June 2025